Evofem Biosciences, Inc. (EVFM)
OTCMKTS
· Delayed Price · Currency is USD
0.0100
+0.0010 (11.11%)
Apr 22, 2025, 4:00 PM EDT
Evofem Biosciences Revenue
In the year 2024, Evofem Biosciences had annual revenue of $19.36M with 6.28% growth. Evofem Biosciences had revenue of $7.10M in the quarter ending December 31, 2024, with 46.81% growth.
Revenue
19.36M
Revenue Growth
+6.28%
P/S Ratio
0.05
Revenue / Employee
605.09K
Employees
32
Market Cap
1.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.36M | 1.15M | 6.28% |
Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
Dec 31, 2020 | 446.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Evofem Biosciences News
- 9 days ago - Evofem Biosciences to Present at Emerging Growth Conference - PRNewsWire
- 4 weeks ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 4 weeks ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 4 weeks ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 2 months ago - Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO - PRNewsWire
- 5 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 6 months ago - Evofem Secures Investor Support for Proposed Merger through Voting Agreements - PRNewsWire
- 8 months ago - Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution - PRNewsWire